D
Cidara Therapeutics, Inc.
CDTX
$22.36
-$0.64-2.78%
D
Sell
8/15/2024Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 8/15/2024 due to a major increase in the solvency index, volatility index and total return index. The quick ratio increased from 0.55 to 4.21.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 8/15/2024 due to a major increase in the solvency index, volatility index and total return index. The quick ratio increased from 0.55 to 4.21.
E
Sell
7/31/2024Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 7/31/2024 due to a decline in the total return index and volatility index.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 7/31/2024 due to a decline in the total return index and volatility index.
D
Sell
7/12/2024Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 7/12/2024 due to an increase in the volatility index.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 7/12/2024 due to an increase in the volatility index.
E
Sell
6/24/2024Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 6/24/2024 due to a decline in the volatility index.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 6/24/2024 due to a decline in the volatility index.
D
Sell
6/5/2024Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 6/5/2024 due to an increase in the volatility index and valuation index.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 6/5/2024 due to an increase in the volatility index and valuation index.
E
Sell
6/3/2024Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 6/3/2024 due to a decline in the volatility index and growth index.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 6/3/2024 due to a decline in the volatility index and growth index.
D
Sell
4/25/2024Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 4/25/2024 due to an increase in the valuation index and growth index. Total revenue increased 38.25% from $12.72M to $17.58M, earnings per share increased from -$1.8102 to -$1.2492, and EBIT increased 29% from -$8.56M to -$6.07M.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 4/25/2024 due to an increase in the valuation index and growth index. Total revenue increased 38.25% from $12.72M to $17.58M, earnings per share increased from -$1.8102 to -$1.2492, and EBIT increased 29% from -$8.56M to -$6.07M.
E
Sell
4/19/2024Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 4/19/2024 due to a decline in the volatility index.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 4/19/2024 due to a decline in the volatility index.
D
Sell
3/28/2024Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 3/28/2024 due to a significant increase in the growth index, volatility index and valuation index. Total revenue increased 67.03% from $7.61M to $12.72M, earnings per share increased from -$0.14 to -$0.0905, and EBIT increased 33.33% from -$12.83M to -$8.56M.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 3/28/2024 due to a significant increase in the growth index, volatility index and valuation index. Total revenue increased 67.03% from $7.61M to $12.72M, earnings per share increased from -$0.14 to -$0.0905, and EBIT increased 33.33% from -$12.83M to -$8.56M.
E
Sell
8/7/2023Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 8/7/2023 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.0317 to -$0.14, EBIT declined 531% from $2.98M to -$12.83M, and total revenue declined 70.7% from $25.99M to $7.61M.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 8/7/2023 due to a significant decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.0317 to -$0.14, EBIT declined 531% from $2.98M to -$12.83M, and total revenue declined 70.7% from $25.99M to $7.61M.
D
Sell
8/4/2023Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 8/4/2023 due to an increase in the valuation index and growth index.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 8/4/2023 due to an increase in the valuation index and growth index.
E
Sell
7/20/2023Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 7/20/2023 due to a decline in the volatility index, total return index and valuation index.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 7/20/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
3/23/2023Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 3/23/2023 due to an increase in the valuation index, total return index and volatility index.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 3/23/2023 due to an increase in the valuation index, total return index and volatility index.
E
Sell
3/14/2023Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D on 3/14/2023 due to a decline in the valuation index.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D on 3/14/2023 due to a decline in the valuation index.
D
Sell
2/9/2023Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from E+ on 2/9/2023 due to an increase in the total return index.
E
Sell
2/8/2023Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D on 2/8/2023 due to a decline in the valuation index.
D
Sell
8/5/2022Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from D- on 8/5/2022 due to an increase in the volatility index and total return index.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from D- on 8/5/2022 due to an increase in the volatility index and total return index.
D
Sell
7/20/2022Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to D- from D on 7/20/2022 due to a decline in the volatility index and valuation index.
Cidara Therapeutics, Inc. (CDTX) was downgraded to D- from D on 7/20/2022 due to a decline in the volatility index and valuation index.
D
Sell
7/5/2022Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from D- on 7/5/2022 due to an increase in the volatility index and total return index.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from D- on 7/5/2022 due to an increase in the volatility index and total return index.
D
Sell
5/31/2022Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 5/31/2022 due to an increase in the valuation index.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 5/31/2022 due to an increase in the valuation index.
E
Sell
5/13/2022Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D on 5/13/2022 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.17 to 0.54, operating cash flow declined 58.37% from -$14.91M to -$23.61M, and the quick ratio declined from 1.91 to 1.41.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D on 5/13/2022 due to a decline in the growth index, valuation index and solvency index. Debt to equity increased from 0.17 to 0.54, operating cash flow declined 58.37% from -$14.91M to -$23.61M, and the quick ratio declined from 1.91 to 1.41.
D
Sell
5/4/2022Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/1/2022Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D on 5/1/2022 due to a decline in the volatility index.
D
Sell
4/21/2022Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from E+ on 04/21/2022.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
D
Sell
3/15/2022Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from D- on 3/15/2022 due to a major increase in the growth index, solvency index and valuation index. The quick ratio increased from 1.21 to 1.91, earnings per share increased from -$0.3651 to -$0.2606, and EBIT increased 7.02% from -$18.04M to -$16.77M.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from D- on 3/15/2022 due to a major increase in the growth index, solvency index and valuation index. The quick ratio increased from 1.21 to 1.91, earnings per share increased from -$0.3651 to -$0.2606, and EBIT increased 7.02% from -$18.04M to -$16.77M.
D
Sell
12/16/2021Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to D- from D on 12/16/2021 due to a significant decline in the growth index, total return index and solvency index. Operating cash flow declined 448.02% from $3.44M to -$11.97M, earnings per share declined from $0.1806 to -$0.37, and EBIT declined 267.42% from $10.77M to -$18.04M.
Cidara Therapeutics, Inc. (CDTX) was downgraded to D- from D on 12/16/2021 due to a significant decline in the growth index, total return index and solvency index. Operating cash flow declined 448.02% from $3.44M to -$11.97M, earnings per share declined from $0.1806 to -$0.37, and EBIT declined 267.42% from $10.77M to -$18.04M.
D
Sell
11/9/2021Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from E+ on 11/09/2021.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index and total return index.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D on 11/8/2021 due to a decline in the volatility index and total return index.
D
Sell
6/17/2021Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from D- on 6/17/2021 due to an increase in the total return index and volatility index.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from D- on 6/17/2021 due to an increase in the total return index and volatility index.
D
Sell
6/2/2021Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to D- from D on 6/2/2021 due to a decline in the volatility index and total return index.
Cidara Therapeutics, Inc. (CDTX) was downgraded to D- from D on 6/2/2021 due to a decline in the volatility index and total return index.
D
Sell
5/18/2021Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from D- on 5/18/2021 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 83.89% from -$11.13M to -$1.79M, earnings per share increased from -$0.49 to -$0.3895, and EBIT increased 15.44% from -$21.55M to -$18.22M.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from D- on 5/18/2021 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 83.89% from -$11.13M to -$1.79M, earnings per share increased from -$0.49 to -$0.3895, and EBIT increased 15.44% from -$21.55M to -$18.22M.
D
Sell
2/26/2021Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to D- from D on 2/26/2021 due to a significant decline in the growth index, total return index and valuation index. EBIT declined 22.93% from -$17.53M to -$21.55M, and earnings per share declined from -$0.41 to -$0.49.
Cidara Therapeutics, Inc. (CDTX) was downgraded to D- from D on 2/26/2021 due to a significant decline in the growth index, total return index and valuation index. EBIT declined 22.93% from -$17.53M to -$21.55M, and earnings per share declined from -$0.41 to -$0.49.
D
Sell
9/21/2020Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to D from D+ on 9/21/2020 due to a decline in the volatility index and total return index.
Cidara Therapeutics, Inc. (CDTX) was downgraded to D from D+ on 9/21/2020 due to a decline in the volatility index and total return index.
D
Sell
9/3/2020Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D+ from D on 9/3/2020 due to an increase in the valuation index.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D+ from D on 9/3/2020 due to an increase in the valuation index.
D
Sell
8/14/2020Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to D from D+ on 8/14/2020 due to a decline in the solvency index and valuation index. Debt to equity increased from 0.2 to 0.24, and the quick ratio declined from 2.38 to 1.93.
Cidara Therapeutics, Inc. (CDTX) was downgraded to D from D+ on 8/14/2020 due to a decline in the solvency index and valuation index. Debt to equity increased from 0.2 to 0.24, and the quick ratio declined from 2.38 to 1.93.
D
Sell
6/26/2020Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D+ from D on 6/26/2020 due to an increase in the total return index and volatility index.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D+ from D on 6/26/2020 due to an increase in the total return index and volatility index.
D
Sell
6/11/2020Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to D from D+ on 6/11/2020 due to a decline in the volatility index.
Cidara Therapeutics, Inc. (CDTX) was downgraded to D from D+ on 6/11/2020 due to a decline in the volatility index.
D
Sell
5/20/2020Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D+ from D on 5/20/2020 due to a large increase in the growth index, solvency index and volatility index. Total revenue increased 39.39% from $1.82M to $2.53M, debt to equity declined from 0.29 to 0.2, and the quick ratio increased from 1.85 to 2.38.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D+ from D on 5/20/2020 due to a large increase in the growth index, solvency index and volatility index. Total revenue increased 39.39% from $1.82M to $2.53M, debt to equity declined from 0.29 to 0.2, and the quick ratio increased from 1.85 to 2.38.
D
Sell
5/1/2020Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the total return index and volatility index.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the total return index and volatility index.
D
Sell
11/12/2019Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 11/12/2019 due to a noticeable increase in the growth index and volatility index. Operating cash flow increased 229.75% from -$12.81M to $16.62M, EBIT increased 121.22% from -$14.27M to $3.03M, and earnings per share increased from -$0.4875 to $0.08.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 11/12/2019 due to a noticeable increase in the growth index and volatility index. Operating cash flow increased 229.75% from -$12.81M to $16.62M, EBIT increased 121.22% from -$14.27M to $3.03M, and earnings per share increased from -$0.4875 to $0.08.
E
Sell
9/19/2018Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 9/19/2018 due to a decline in the total return index and volatility index.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 9/19/2018 due to a decline in the total return index and volatility index.
D
Sell
9/4/2018Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 9/4/2018 due to an increase in the solvency index, growth index and total return index. Debt to equity declined from 0.19 to 0.12, the quick ratio increased from 5.77 to 6.92, and EBIT increased 9.86% from -$16.81M to -$15.15M.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 9/4/2018 due to an increase in the solvency index, growth index and total return index. Debt to equity declined from 0.19 to 0.12, the quick ratio increased from 5.77 to 6.92, and EBIT increased 9.86% from -$16.81M to -$15.15M.
E
Sell
5/11/2018Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 5/11/2018 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 55.12% from -$9.49M to -$14.72M, EBIT declined 24.9% from -$13.46M to -$16.81M, and earnings per share declined from -$0.689 to -$0.8016.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 5/11/2018 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 55.12% from -$9.49M to -$14.72M, EBIT declined 24.9% from -$13.46M to -$16.81M, and earnings per share declined from -$0.689 to -$0.8016.
D
Sell
11/9/2017Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 11/9/2017 due to a major increase in the growth index, total return index and volatility index. EBIT increased 26.28% from -$16.62M to -$12.25M, and earnings per share increased from -$0.9889 to -$0.73.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 11/9/2017 due to a major increase in the growth index, total return index and volatility index. EBIT increased 26.28% from -$16.62M to -$12.25M, and earnings per share increased from -$0.9889 to -$0.73.
E
Sell
9/1/2017Downgrade
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 9/1/2017 due to a significant decline in the volatility index, growth index and efficiency index. Net income declined 24.23% from -$13.4M to -$16.65M, EBIT declined 24.01% from -$13.4M to -$16.62M, and earnings per share declined from -$0.7977 to -$0.9889.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E+ from D- on 9/1/2017 due to a significant decline in the volatility index, growth index and efficiency index. Net income declined 24.23% from -$13.4M to -$16.65M, EBIT declined 24.01% from -$13.4M to -$16.62M, and earnings per share declined from -$0.7977 to -$0.9889.
D
Sell
1/4/2016Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 1/4/2016 due to a large increase in the efficiency index, volatility index and total return index. Net income increased 43.03% from -$6.41M to -$9.17M.
Cidara Therapeutics, Inc. (CDTX) was upgraded to D- from E+ on 1/4/2016 due to a large increase in the efficiency index, volatility index and total return index. Net income increased 43.03% from -$6.41M to -$9.17M.
E
Sell
10/1/2015Upgraded
Cidara Therapeutics, Inc. (CDTX) was upgraded to E+ from E on 10/1/2015 due to a major increase in the growth index, solvency index and total return index. The quick ratio increased from 15.26 to 39.86.
Cidara Therapeutics, Inc. (CDTX) was upgraded to E+ from E on 10/1/2015 due to a major increase in the growth index, solvency index and total return index. The quick ratio increased from 15.26 to 39.86.
E
Sell
7/10/2015None
Cidara Therapeutics, Inc. (CDTX) was downgraded to E from U on 07/10/2015.
Cidara Therapeutics, Inc. (CDTX) was downgraded to E from U on 07/10/2015.
NASDAQ
03/13/2025 4:00PM Eastern
Quotes delayed
